Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by George Bondi on Jun 6th, 2026

Omeros Corporation (NASDAQ:OMER – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $40.3333.

OMER has been the topic of several research analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Weiss Ratings lowered Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Omeros in a research note on Thursday, May 14th. Finally, Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd.

Read Our Latest Stock Analysis on OMER

Insider Activity at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of Omeros stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the sale, the director directly owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 12.90% of the company’s stock.

Institutional Trading of Omeros

A number of hedge funds have recently made changes to their positions in OMER. Acadian Asset Management LLC acquired a new stake in shares of Omeros during the first quarter valued at about $357,000. XTX Topco Ltd acquired a new stake in shares of Omeros during the second quarter valued at about $191,000. Invesco Ltd. boosted its stake in shares of Omeros by 34.1% during the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 29,644 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Omeros during the second quarter valued at about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Down 4.5%

NASDAQ:OMER opened at $9.79 on Monday. The stock’s 50-day simple moving average is $12.26 and its 200 day simple moving average is $11.82. The firm has a market capitalization of $708.60 million, a PE ratio of 13.99 and a beta of 2.52. Omeros has a twelve month low of $2.95 and a twelve month high of $17.65.

Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to analyst estimates of $4.19 million. On average, analysts anticipate that Omeros will post -0.94 EPS for the current fiscal year.

About Omeros

(Get Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.